15.02.2017
Appointment of Mario Ricard as COO and member of the Executive Committee
Acino announces the appointment of Mario Ricard as Chief Operations Officer and member of the Executive Committee effective February 15,...
News
31.10.2016
Acino launches its new corporate brand identity
Acino is very pleased to launch today its new corporate brand identity and its new website under the URL www.acino.swiss.The new...
25.07.2016
Acino divests its patch business to Luye Pharma Group Ltd.
Today Acino International AG and Acino Pharma AG (together “Acino”) have signed a definitive agreement with Luye Pharma Group Ltd....
13.07.2016
Acino to acquire Takeda’s manufacturing plant in Põlva, Estonia
Acino and Takeda announced today that Acino will acquire Takeda’s manufacturing site in Põlva, Estonia.The packaging site in Estonia is...
28.06.2016
Acino acquires the Middle East and North Africa (MENA) operations and product rights from Norgine B.V.
Acino today announced that it has completed the acquisition of the MENA operations and product rights for MOVICOL®, MOVIPREP®, KLEAN-PREP® and...
19.04.2016
Appointment of Kalle Känd as CEO Acino Group
Acino International announces today the appointment of Kalle Känd as Chief Executive Officer Acino Group as of April 19, 2016....
07.10.2015
Acino continues expanding its emerging markets business by acquiring Pharma Start
Effective October 1, 2015, Acino Pharma, an international pharmaceutical company headquartered in Switzerland, acquires Pharma Start, the 9th largest local...
04.09.2015
Acino launches the first generic Rivastigmine patch in the USA
Acino’s rivastigmine patch is the first generic alternative to the originator product making the medical treatment of Alzheimer’s more affordable...
17.02.2015
Acino welcomes German court ruling on rivastigmine
Acino announces the achievement of another judicial success in the ongoing German intellectual property litigation proceedings regarding its generic rivastigmine...
